Stocks:
5,169
ETFs:
2,288
Exchanges:
11
Market Cap:
$65.09T
24h Vol:
$8.59B
Dominance:
MSFT:4.90%
Stocklytics Platform
Asset logo for symbol MDXG
MiMedx Group
MDXG
91
$6.83arrow_drop_down1.15%-$0.08
High Quality
High Growth

Performance History

Chart placeholder
Key Stats
Open$6.84
Prev. Close$6.91
EPS0.52
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
Market Cap$1.05B
PE Ratio13.13
LOWHIGH
Day Range6.76
6.97
52 Week Range5.51
9.27
Ratios
P/B Ratio6.64
Revenue$321.47M
Operating M. %15.64%
Earnings$67.43M
Earnings Growth %323.33%
EBITDA Margin %16.79%
ROE %68.13%
EPS0.52

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

info
There's no data available for Analyst Forecast

Analyst Ratings

info
There's no data available for Analyst Ratings

Correlated Companies

PRICE$878.45
24H (%)arrow_drop_down0.55%
24H ($)-$4.88
MARKET CAP$771.28B
PRICE$497.12
24H (%)arrow_drop_down0.03%
24H ($)-$0.17
MARKET CAP$443.63B
PRICE$145.53
24H (%)arrow_drop_up0.06%
24H ($)$0.09
MARKET CAP$347.62B
PRICE$129.48
24H (%)arrow_drop_up0.08%
24H ($)$0.11
MARKET CAP$318.88B

About MiMedx Group (MDXG)

MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins. The company's patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. Its products include EpiFix, a semi-permeable protective barrier membrane product used for the treatment of chronic wounds, including diabetic foot ulcers, venous leg ulcers, and pressure ulcers; AmnioFix, a semi-permeable protective barrier allograft, which comprises dehydrated human amnion/chorion membrane for use in surgical recovery applications; EpiCord and AmnioCord are dehydrated human umbilical cord allografts that are used to provide a protective environment for the healing process, as well as used in the advanced wound care and surgical recovery applications; and AMNIOBURN a semi-permeable protective barrier allograft used in the treatment of partial-thickness and full-thickness burns, as well as lead product includes mdHACM, a micronized form of AMNIOFIX, supplied in powder form. The company's products have applications primarily in the areas of wound care, burn, surgical, and non-operative sports medicine sectors of healthcare. It also sells allografts for dental applications on an original equipment manufacturer basis. The company sells its products through direct sales force and independent sales agents, as well as through independent distributors primarily in the United States. MiMedx Group, Inc. was incorporated in 2011 and is headquartered in Marietta, Georgia.

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Joseph H. Capper
Headquarters
Marietta
Employees
867
Exchange
NASDAQ
add MiMedx Group to watchlist

Keep an eye on MiMedx Group

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help
What is the market capitalization of MiMedx Group (MDXG)?

MiMedx Group (MDXG) has a market capitalization of $1.06B. The average daily trading volume is 588.26K, indicating the stock's liquidity and investor engagement.

help
What is MiMedx Group's (MDXG) price per share?

The current price per share for MiMedx Group (MDXG) is $6.83. The stock has seen a price change of -$0.08 recently, indicating a -1.16% change. This reflects the stock's recent market performance and investor sentiment.

help
What is the 52-week high and low for MiMedx Group (MDXG)?

For MiMedx Group (MDXG), the 52-week high is $9.27, which is 35.72% from the current price. The 52-week low is $5.51, the current price is 23.96% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help
Is MiMedx Group (MDXG) a growth stock?

MiMedx Group (MDXG) has shown an average price growth of 0.41% over the past three years. It has received a score of 55 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying MiMedx Group as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help
What is MiMedx Group (MDXG) stock price performance year to date (YTD)?

As of the latest data, MiMedx Group (MDXG) has a year-to-date price change of -13.21%. Over the past month, the stock has experienced a price change of -15.47%. Over the last three months, the change has been -13.32%. Over the past six months, the figure is -23.77%.

help
Is MiMedx Group (MDXG) a profitable company?

MiMedx Group (MDXG) has a net income of $67.44M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 83.01% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 15.64% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $321.48M, with a revenue growth rate of 20.03%, providing insight into the company's sales performance and growth. The gross profit is $266.84M. Operating income is noted at $37.12M. Furthermore, the EBITDA is $56.78M.

News

email

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Take Your Investments to a Whole New Level